Playback speed
10 seconds
SGO 2024 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Efficacy & Safety of Tisotumab Vedotin vs. Investigator's Choice of Chemo in 2L/3L Recurrent/Metastatic Cervical Cancer"
By
Insights from 2024 SGO Annual Meeting
FEATURING
Brian Slomovitz
By
Insights from 2024 SGO Annual Meeting
FEATURING
Brian Slomovitz
311 views
April 12, 2024
Login to view comments.
Click here to Login